Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod and Nivolumab in Stage IIIB-D Melanoma
NCT04401995Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vidutolimod in melanoma. Started Sep 2020; status: completed.
02
Drugs
vidutolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04401995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401995.